At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Regina Barragán, Postdoctoral Fellow at the Genitourinary Clinic, Medical Oncology and Therapeutics, City of Hope, delivered a detailed presentation on “The Current State of Renal Oncology in Mexico.” She outlined how RCC is becoming an increasingly important public health concern, with incidence rising by nearly 70% and mortality by almost 90% in recent years—outpacing trends in the United States and across the Americas.
Despite Mexico’s large oncology community, most specialists are concentrated in a few major cities, leaving rural areas underserved. Patients are often diagnosed younger and at later stages, with stark disparities in surgical and systemic treatment between public and private sectors. Access to modern IO/TKI combinations and second- or third-line therapies remains limited, while national registries provide only partial, low-quality data. Dr. Barragán stressed the urgent need to improve epidemiological surveillance, decentralize multidisciplinary care, and expand participation in clinical trials to ensure Mexican patients benefit from advances that are already reshaping renal oncology worldwide.
Join us in this conversation.